News - Page 144 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Psychedelic Bulletin: atai Launches Precision Psychiatry Company; DEA Proposes Further Increase to Psychedelics Production Quotas

Psychedelic Bulletin: atai Launches Precision Psychiatry Company; DEA Proposes Further Increase to Psychedelics Production Quotas

Post published:October 16, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Research Bulletin: September 2021

Psychedelic Research Bulletin: September 2021

Post published:October 16, 2021
Post category:Psychedelics Research Review

Read more about the article Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the COPE Program with InterVivo Solutions

Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the COPE Program with InterVivo Solutions

Post published:October 14, 2021
Post category:Press Release

Read more about the article Levitee Labs Appoints Dr. Mohammed Mosli as Chief People Officer of Levitee Clinics and Pharmacies in Alberta, Canada

Levitee Labs Appoints Dr. Mohammed Mosli as Chief People Officer of Levitee Clinics and Pharmacies in Alberta, Canada

Post published:October 14, 2021
Post category:Press Release

Read more about the article Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study

Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study

Post published:October 13, 2021
Post category:Press Release

Read more about the article MindMed Joins Clinical Trials Transformation Initiative

MindMed Joins Clinical Trials Transformation Initiative

Post published:October 13, 2021
Post category:Press Release

Read more about the article PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome

PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome

Post published:October 13, 2021
Post category:Press Release

Read more about the article MYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Million Clinical Trial

MYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Million Clinical Trial

Post published:October 13, 2021
Post category:Press Release

Read more about the article atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)

atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)

Post published:October 11, 2021
Post category:Press Release

Numinus Upgrades Psychedelics Lab to Increase Research Service Capabilities

Post published:October 8, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.